Fainting schoolgirls wipe $A1bn off market value of Gardasil producer
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39238.479479.94 (Published 07 June 2007) Cite this as: BMJ 2007;334:1195- Simon Chapman, professor of public health,
- Ross MacKenzie, research officer
- School of Public Health, University of Sydney
- Correspondence to:S Chapmansc{at}med.usyd.edu.au
On 22 May news broke that 25 girls at a Catholic high school in Melbourne who had just had their first injection of Gardasil, the vaccine against human papillomavirus (HPV), presented to the school's sick bay with symptoms that included headache, nausea, and dizziness. CSL, the vaccine's Australian developer, reports that four pupils were sent to hospital for further examination. It said, “One had chest pain and palpitations; she had a past history of these symptoms. She was discharged the same day. The second had hyperventilation paraesthesiae and was sent home the same day. The third and fourth had neurological symptoms and were admitted. The fourth girl had reported progressive muscular weakness. Overnight both got better and were seen by the neurologist in the morning who diagnosed non-organic illness.”
Other than the mother of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.